
One 80-mg tablet, orally,
once a day
TAGRISSO tablets may be taken with or without food
TAGRISSO can be dissolved into non-carbonated water and swallowed or taken through an NG tube*
Target organ | Adverse reaction† | Recommended dose modification |
---|---|---|
Pulmonary |
ILD/Pneumonitis |
Permanently discontinue TAGRISSO |
Cardiac |
QTc interval greater than 500 msec on at least 2 separate ECGs |
Withhold TAGRISSO until QTc interval is less than 481 msec or recovery to baseline if baseline QTc is greater than or equal to 481 msec, then restart at a reduced dose (40 mg) |
QTc interval prolongation with signs/symptoms of serious arrhythmia |
Permanently discontinue TAGRISSO |
|
Other |
Grade 3 or higher adverse reaction |
Withhold TAGRISSO for up to 3 weeks |
If Grade 3 or higher adverse reaction improves to Grade 0–2 after withholding of TAGRISSO for up to 3 weeks |
TAGRISSO may be restarted at the same dose (80 mg) or a lower dose (40 mg) |
|
Grade 3 or higher adverse reaction that does not improve to Grade 0–2 after withholding for up to 3 weeks |
Permanently discontinue TAGRISSO |
Reference: 1. AstraZeneca Pharmaceuticals. TAGRISSO® (osimertinib). Summary of Product Characteristics, 2020.